losartan has been researched along with Fatty Liver in 14 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of losartan-an angiotensin II type 1 receptor (AT1R) antagonist- and telmisartan-an AT1R blocker with insulin-sensitizing properties-, on the hepatic expression of plasminogen activator inhibitor-1 (PAI-1) in a rat model of nonalcoholic fatty liver disease (NAFLD)." | 7.75 | Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. ( Burgueño, AL; Carabelli, J; Pirola, CJ; Rosselli, MS; Schuman, M; Sookoian, S, 2009) |
| " The aim of this study was to evaluate the effects of losartan or amlodipine alone or combined with simvastatin on hepatic steatosis degree, and on insulin sensitivity in normocholesterolemic, hypertensive patients with nonalcoholic hepatic steatosis." | 5.16 | Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2012) |
| "The evaluation of the efficacy of ursodeoxycholic acid (UDCA), pentoxifylline, losartan, and atorvastatin in non-alcoholic steatohepatitis (NASH) treatment." | 5.12 | Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. ( Georgescu, EF; Georgescu, M, 2007) |
| " We treated patients who had NASH and hypertension with losartan, an angiotensin II receptor antagonist for 48 weeks." | 4.83 | [Clinical utility of angiotensin II receptor antagonist]. ( Haneda, M; Nakamura, K; Yokohama, S, 2006) |
| "To evaluate the effect of losartan-an angiotensin II type 1 receptor (AT1R) antagonist- and telmisartan-an AT1R blocker with insulin-sensitizing properties-, on the hepatic expression of plasminogen activator inhibitor-1 (PAI-1) in a rat model of nonalcoholic fatty liver disease (NAFLD)." | 3.75 | Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. ( Burgueño, AL; Carabelli, J; Pirola, CJ; Rosselli, MS; Schuman, M; Sookoian, S, 2009) |
| "The therapeutic efficacy of angiotensin II receptor antagonist, losartan, was studied in patients with nonalcoholic steatohepatitis (NASH)." | 3.72 | Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. ( Aso, K; Haneda, M; Hasegawa, T; Miyokawa, N; Nakamura, K; Okada, M; Okamoto, S; Tokusashi, Y; Yokohama, S; Yoneda, M, 2004) |
| "ARB markedly inhibited liver fibrosis development along with suppression of the number of Ac-HSC and TGF-β." | 1.39 | Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. ( Aihara, Y; Douhara, A; Fukui, H; Kaji, K; Kawaratani, H; Moriya, K; Namisaki, T; Noguchi, R; Shirai, Y; Yoshiji, H, 2013) |
| "Nonalcoholic steatohepatitis (NASH) is a metabolic disorder of the liver that may evolve into fibrosis or cirrhosis." | 1.34 | Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. ( Accatino, L; Aguayo, G; Arrese, M; Duarte, I; Ibañez, P; Miquel, JF; Pizarro, M; Solis, N, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, YY | 1 |
| Lee, PC | 1 |
| Huang, YT | 1 |
| Lee, WP | 1 |
| Kuo, YJ | 1 |
| Lee, KC | 1 |
| Hsieh, YC | 1 |
| Lee, TY | 1 |
| Lin, HC | 1 |
| Georgescu, EF | 2 |
| Rosselli, MS | 1 |
| Burgueño, AL | 1 |
| Carabelli, J | 1 |
| Schuman, M | 1 |
| Pirola, CJ | 2 |
| Sookoian, S | 2 |
| Kaji, K | 2 |
| Yoshiji, H | 2 |
| Kitade, M | 1 |
| Ikenaka, Y | 1 |
| Noguchi, R | 2 |
| Shirai, Y | 2 |
| Aihara, Y | 2 |
| Namisaki, T | 2 |
| Yoshii, J | 1 |
| Yanase, K | 1 |
| Tsujimoto, T | 1 |
| Kawaratani, H | 2 |
| Fukui, H | 2 |
| Torres, DM | 1 |
| Jones, FJ | 1 |
| Shaw, JC | 1 |
| Williams, CD | 1 |
| Ward, JA | 1 |
| Harrison, SA | 1 |
| Corey, KE | 1 |
| Chalasani, N | 1 |
| Fogari, R | 1 |
| Maffioli, P | 1 |
| Mugellini, A | 1 |
| Zoppi, A | 1 |
| Lazzari, P | 1 |
| Derosa, G | 1 |
| Douhara, A | 1 |
| Moriya, K | 1 |
| Yokohama, S | 3 |
| Yoneda, M | 2 |
| Haneda, M | 3 |
| Okamoto, S | 2 |
| Okada, M | 2 |
| Aso, K | 2 |
| Hasegawa, T | 2 |
| Tokusashi, Y | 2 |
| Miyokawa, N | 2 |
| Nakamura, K | 3 |
| Tamaki, Y | 1 |
| Aoshima, M | 1 |
| Georgescu, M | 1 |
| Ibañez, P | 1 |
| Solis, N | 1 |
| Pizarro, M | 1 |
| Aguayo, G | 1 |
| Duarte, I | 1 |
| Miquel, JF | 1 |
| Accatino, L | 1 |
| Arrese, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH)[NCT04193982] | Phase 3 | 250 participants (Anticipated) | Interventional | 2021-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for losartan and Fatty Liver
| Article | Year |
|---|---|
Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Fat | 2008 |
[Clinical utility of angiotensin II receptor antagonist].
Topics: Angiotensin II Type 1 Receptor Blockers; Fatty Liver; Humans; Hypertension; Insulin Resistance; Live | 2006 |
3 trials available for losartan and Fatty Liver
| Article | Year |
|---|---|
Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biopsy; Drug Therapy, Combination; | 2011 |
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholagogues and Choleretics; | 2007 |
9 other studies available for losartan and Fatty Liver
| Article | Year |
|---|---|
Involvement of the HIF-1α and Wnt/β-catenin pathways in the protective effects of losartan on fatty liver graft with ischaemia/reperfusion injury.
Topics: Animals; beta Catenin; Diet, High-Fat; Fatty Liver; Glycoproteins; Hypoxia-Inducible Factor 1, alpha | 2014 |
Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dietary Fats; Disease M | 2009 |
Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Topics: Administration, Oral; Angiogenesis Inhibitors; Angiotensin II; Angiotensin II Type 1 Receptor Blocke | 2011 |
Targeting the renin-angiotensin system: potential beneficial effects of the angiotensin II receptor blockers in patients with nonalcoholic steatohepatitis.
Topics: Fatty Liver; Female; Humans; Losartan; Male; Metformin; Thiazolidinediones | 2011 |
Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?
Topics: Fatty Liver; Female; Humans; Losartan; Male; Metformin; Non-alcoholic Fatty Liver Disease; Rosiglita | 2011 |
Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Communication; Disease Models | 2013 |
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.
Topics: Adult; Angiotensin Receptor Antagonists; Biomarkers; Fatty Liver; Female; Ferritins; Hepatitis; Huma | 2004 |
Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Fatty Liver; Female; Humans; Liver; Liver Cirr | 2006 |
Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Choline Deficiency; Disease Models, Animal; Fatty | 2007 |